ALXONasdaqPharmaceutical PreparationsFiscal year ends December 31
ALX ONCOLOGY HOLDINGS INC
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026
$1.14+0.08 (+7.55%)
Close on Oct 19, 2026
- Market cap
- $154.63M
- P/E (TTM)
- –
- Dividend yield
- –
Alx Oncology statistics
Financials through Jun 30, 2026, price as of Oct 19, 2026, median of Pharmaceutical Preparations companies for comparison
Valuation
| Measure | Alx Oncology | Industry median |
|---|---|---|
| Market Cap | $157.64M | $166.30M |
| Enterprise Value | $29.11M | $88.19M |
| PB Ratio | 1.16 | 2.03 |
| P/TBV Ratio | 1.16 | 2.29 |
Income (trailing twelve months)
| Measure | Alx Oncology | Industry median |
|---|---|---|
| Operating Income | -$82.55M | -$21.40M |
| Net Income | -$80.89M | -$22.46M |
| EBITDA | -$81.95M | -$16.91M |
| EPS (Diluted) | -$1.13 | -$0.83 |
Returns
| Measure | Alx Oncology | Industry median |
|---|---|---|
| Return on Equity (ROE) | -80.6% | -53.2% |
| Return on Assets (ROA) | -63.2% | -40.9% |
| Return on Invested Capital (ROIC) | -4651.6% | -32.4% |
| Return on Capital Employed (ROCE) | -56.5% | -38.1% |
Balance sheet
| Measure | Alx Oncology | Industry median |
|---|---|---|
| Cash & Short-Term Investments | $138.23M | $61.43M |
| Total Debt | $9.71M | $118.52M |
| Net Cash (Debt) | $128.52M | $15.35M |
| Net Cash Per Share | $0.93 | $0.66 |
| Equity (Book Value) | $136.19M | $49.09M |
| Book Value Per Share | $0.98 | $1.37 |
| Tangible Book Value | $136.19M | $23.52M |
| Working Capital | $128.68M | $76.81M |
Financial position
| Measure | Alx Oncology | Industry median |
|---|---|---|
| Current Ratio | 9.71 | 3.34 |
| Quick Ratio | 9.35 | 2.44 |
| Debt / Equity | 0.07 | 0.52 |
| Interest Coverage | -58.67 | -6.26 |
Cash flow (trailing twelve months)
| Measure | Alx Oncology | Industry median |
|---|---|---|
| Operating Cash Flow | -$70.78M | -$12.35M |
| Capital Expenditures | -$172.00K | -$1.08M |
| Free Cash Flow | -$70.95M | -$20.22M |
| FCF Per Share | -$0.51 | -$0.42 |
Efficiency
| Measure | Alx Oncology | Industry median |
|---|---|---|
| Profits Per Employee | -$1.88M | -$703.34K |
| Employee Count | 43 | 74 |
Dividends and yields
| Measure | Alx Oncology | Industry median |
|---|---|---|
| Earnings Yield | -51.3% | -23.3% |
| FCF Yield | -45.0% | -8.72% |
| Buyback Yield | -0.84% | -0.59% |
| Shareholder Yield | -0.84% | 0.00% |
Shares
| Measure | Alx Oncology | Industry median |
|---|---|---|
| Shares Outstanding | 138,277,000 | 58,127,000 |
| Shares Change (YoY) | 63.0% | 10.9% |
| Shares Change (QoQ) | 0.00% | 0.54% |
| Float | 106,134,000 | 49,136,700 |
| Shares Held by Insiders | 23.2% | 11.6% |
| Shares Held by Institutions | 76.6% | 59.4% |
Scores
| Measure | Alx Oncology | Industry median |
|---|---|---|
| Altman Z-Score | -3.50 | -0.22 |
| Piotroski F-Score | 0 | 4 |
Calculated by StockData from Alx Oncology's SEC filings and the latest closing price. Hover a measure to see its formula. The grey column is the median of companies in the same industry group (two-digit SIC code); green or red marks a better or worse value than that median.